|Assessment process complete
|For the treatment of patients with chronic lymphocytic leukaemia who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p) or TP53 mutation in patients not suitable for chemoimmunotherapy.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Assessment Recommended
|Full pharmacoeconomic assessment commissioned by HSE
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not recommended.
The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with CLL who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p)/TP53 mutation in patients not suitable for chemo-immunotherapy, has not been demonstrated and therefore it is not recommended for reimbursement at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.